DeVita Vt is a scholar working on Pathology and Forensic Medicine, Pulmonary and Respiratory Medicine and Oncology.
According to data from OpenAlex, DeVita Vt has authored 52 papers receiving a total of 1.1k indexed citations (citations by other indexed papers that have themselves been cited), including 17 papers in Pathology and Forensic Medicine, 16 papers in Pulmonary and Respiratory Medicine and 15 papers in Oncology. Recurrent topics in DeVita Vt's work include Lymphoma Diagnosis and Treatment (17 papers), Lung Cancer Treatments and Mutations (12 papers) and Chronic Lymphocytic Leukemia Research (8 papers). DeVita Vt is often cited by papers focused on Lymphoma Diagnosis and Treatment (17 papers), Lung Cancer Treatments and Mutations (12 papers) and Chronic Lymphocytic Leukemia Research (8 papers). DeVita Vt collaborates with scholars based in United States. DeVita Vt's co-authors include Dedrick Rl, Fisher Ri, Young Rc, RC Young, Chabner Ba, Canellos Gp, Larry Norton, T Anderson, Oliverio Vt and Johnson Re and has published in prestigious journals such as PubMed and Munich Personal RePEc Archive (Ludwig Maximilian University of Munich).
In The Last Decade
DeVita Vt
51 papers
receiving
1.0k citations
Hit Papers
What are hit papers?
Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies
if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the
same subfield and year (this is the minimum needed to enter the top 1%, not the average
within it), or reaches the top citation threshold in at least one of its specific research
topics.
This map shows the geographic impact of DeVita Vt's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by DeVita Vt with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites DeVita Vt more than expected).
This network shows the impact of papers produced by DeVita Vt. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by DeVita Vt. The network helps show where DeVita Vt may publish in the future.
Co-authorship network of co-authors of DeVita Vt
This figure shows the co-authorship network connecting the top 25 collaborators of DeVita Vt.
A scholar is included among the top collaborators of DeVita Vt based on the total number of
citations received by their joint publications. Widths of edges
represent the number of papers authors have co-authored together.
Node borders
signify the number of papers an author published with DeVita Vt. DeVita Vt is excluded from
the visualization to improve readability, since they are connected to all nodes in the network.
All Works
20 of 20 papers shown
1.
Vt, DeVita, et al.. (2006). The cell cycle: Probing new molecular determinants of resistance and sensitivity to cytotoxic agents.. PubMed. 1(1). 15–21.2 indexed citations
2.
Vt, DeVita, et al.. (1992). The use of combination chemotherapy in the treatment of early stage Hodgkin's disease.. PubMed. 155–65.8 indexed citations
3.
Vt, DeVita, et al.. (1989). NCI's breast cancer clinical alert: rationale and results.. PubMed. 35(8). 49–55.
4.
Vt, DeVita. (1987). The evolution of chemotherapy of lymphomas of adults.. PubMed. 1(6). 467–85.8 indexed citations
Vt, DeVita. (1985). What are clinical trials all about?. PubMed. 2(3). 36–36.2 indexed citations
7.
Vt, DeVita. (1984). Contrasting viewpoints on cancer drug development: the Wooldridge and Richardson reports.. PubMed. 68(1). 339–40.1 indexed citations
8.
Rc, Young, et al.. (1982). Chemotherapy for Hodgkin's disease: the remaining challenges.. PubMed. 66(4). 925–36.25 indexed citations
9.
Gw, Geelhoed, et al.. (1979). Clinical characteristics of Pneumocystis carinii pneumonia.. PubMed. 45(5). 293–304.4 indexed citations
Vt, DeVita, et al.. (1978). Combination therapy of the lymphomas.. PubMed. 15(4). 431–57.11 indexed citations
12.
Ba, Chabner, et al.. (1977). Sequential staging in non-Hodgkin's lymphoma.. Munich Personal RePEc Archive (Ludwig Maximilian University of Munich). 61(6). 993–7.34 indexed citations
13.
Vt, DeVita. (1977). Proceedings of the Conference on non-Hodgkin's lymphomas: summary of symposium.. PubMed. 61(6). 1223–7.3 indexed citations
14.
Vt, DeVita, et al.. (1975). Reversible penile calcifications associated with bleomycin (NSC-125066)-induced pulmonary toxicity.. Munich Personal RePEc Archive (Ludwig Maximilian University of Munich). 59(5). 1039–1041.4 indexed citations
15.
Ba, Chabner, Robert W. Sponzo, S M Hubbard, et al.. (1974). High-dose intermittent intravenous infusion of procarbazine (NSC-77213).. PubMed. 57(3). 361–3.7 indexed citations
16.
Vt, DeVita. (1973). Combined drug treatment of Hodgkin's disease: remission induction, remission duration, and survival; an appraisal.. PubMed. 36. 373–9.9 indexed citations
17.
Vt, DeVita, et al.. (1973). Intensive chemotherapy for Hodgkin's disease: long-term complications.. PubMed. 36. 447–54.25 indexed citations
18.
Vt, DeVita, et al.. (1971). Effects of 1-(2-chloroethyl)-3-cyclohexyl-1-nitrosourea (CCNU; NSC-79037) and its degradation products on progression of L1210 cells through the cell cycle.. PubMed. 55(3). 215–20.8 indexed citations
19.
Vt, DeVita, Leslie Wiener, & Rashid A. Massumi. (1965). ANTEPARTUM THROMBOPHLEBITIS AND PULMONARY EMBOLIZATION. REPORT OF A CASE AND REVIEW OF THE LITERATURE.. PubMed. 34. 177–80.2 indexed citations
20.
Vt, Oliverio, et al.. (1964). SOME PHARMACOLOGIC PROPERTIES OF A NEW ANTITUMOR AGENT, N-ISOPROPYL-ALPHA-(2-METHYLHYDRAZINO)-P-TOLUAMIDE, HYDROCHLORIDE (NSC-77213).. PubMed. 42. 1–7.20 indexed citations
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive
bibliographic database. While OpenAlex provides broad and valuable coverage of the global
research landscape, it—like all bibliographic datasets—has inherent limitations. These include
incomplete records, variations in author disambiguation, differences in journal indexing, and
delays in data updates. As a result, some metrics and network relationships displayed in
Rankless may not fully capture the entirety of a scholar's output or impact.